GlassScriptPhysician profile
Louis Saade
NPI 1164863593
$10,131.96
in general payments reported to CMS, 2019-2025
32 companies · $3,528 in 2025
The $3,528 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.66 · 2022: $430 · 2023: $1,488 · 2024: $4,647 · 2025: $3,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,291 · Consulting Fee: $1,216 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,290.95 |
| Consulting Fee | $1,216.00 |
| Education | $156.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,128.25 | 2024-2025 | Tavneos, Evenity, Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,325.16 | 2022-2025 | |
| Abbvie INC. | $1,124.33 | 2022-2025 | Rinvoq, Humira, Skyrizi |
| Ucb, INC. | $985.91 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $511.06 | 2023-2025 | |
| Janssen Biotech, INC. | $469.59 | 2023-2025 | Tremfya, Simponi Aria |
| Sobi, INC | $399.27 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $368.62 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Astrazeneca Pharmaceuticals LP | $368.59 | 2023-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $367.74 | 2022-2025 | Strensiq |
| Glaxosmithkline, LLC. | $273.71 | 2022-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $229.79 | 2024-2025 | Idacio |
| Invivyd INC | $157.91 | 2024-2025 | Pemgarda |
| Lilly USA, LLC | $154.02 | 2023-2025 | Taltz |
| Sandoz INC. | $137.65 | 2023-2025 | Hyrimoz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $134.41 | 2023-2025 | Lupkynis |
| Radius Health, INC. | $128.59 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $118.03 | 2023 | Orencia |
| Genzyme Corporation | $94.05 | 2023-2025 | |
| Genentech USA, INC. | $86.18 | 2024-2025 | Actemra, Gazyva |
| Depuy Synthes Sales INC. | $81.01 | 2024-2025 | Orthovisc, Monovisc |
| Kyowa Kirin, INC. | $76.77 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.31 | 2024-2025 | Spevigo |
| Horizon Therapeutics Plc | $65.83 | 2023 | Krystexxa |
| Tersera Therapeutics LLC | $50.94 | 2024-2025 | Quzyttir |
| Mallinckrodt Hospital Products INC. | $49.24 | 2025 | Acthar |
| Fidia Pharma USA INC. | $42.26 | 2025 | Hymovis, Triluron |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.66 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $30.41 | 2024 | Arcalyst |
| Organon LLC | $25.58 | 2023 | Renflexis, Hadlima |
| Alvogen INC | $23.91 | 2024 | Teriparatide |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Saade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.